Beam Therapeutics Inc.

ESCAPE

Engineered Stem Cell Antibody Paired Evasion — non-genotoxic conditioning platform combining antibody-based conditioning with multiplex gene edited HSCs; applicable ex vivo or in vivo including for sickle cell disease

Targets: CD117

Base Editing Platform

Proprietary base editing technology enabling precision genetic medicines that target a single base in the genome without double-stranded DNA breaks, using CRISPR-guided deaminase enzymes. Supports ex vivo and in vivo delivery modalities across hematology and other disease areas including sickle cell disease and beta-thalassemia.

Apellis Complement Base Editing Collaboration · Apellis Pharmaceuticals

Research collaboration using Beam's base editing technology to discover treatments for complement system-driven diseases across six programs targeting specific genes in the complement system in various organs including the eye, liver, and brain. Apellis holds exclusive option rights to license any or all programs.